Meta-analysis of 4 studies (19,090 people with gout) using reconstructed individual data: febuxostat vs allopurinol had lower cardiovascular risk at 0–12 (HR 0.89), 12–24 (0.58) and 24–48 months (0.86), but not beyond 48 months (HR 1.09, 0.81–1.46).
Meta-analysisn = 19,090
Wei et al. Time-varying cardiovascular risk of febuxostat vs. allopurinol in gout: a one-stage meta-analysis